Sign In
Buy RNXT
$0.96
+0.0171 (+1.82%)
At Close: Jul 31, 2026
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
04:05pm, Monday, 30'th Mar 2026
RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipa
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
08:30am, Thursday, 26'th Mar 2026
TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath ® as a Stand-Alone Device for D
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
08:30am, Monday, 23'rd Mar 2026
Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestones Company has the funding, business plan, leadership and infras
MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies
RenovoRx Announces $10 Million at Market Private Placement
08:35am, Wednesday, 18'th Mar 2026
Bolstered Cash Position Expected to Capitalize the Company's Momentum Towards Important Milestones, Including Breakeven Operations and Trial Data
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
08:30am, Friday, 27'th Feb 2026
Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
08:30am, Thursday, 26'th Feb 2026
MOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
RenovoRx Establishes RenovoCath® Medical Advisory Board
08:30am, Tuesday, 10'th Feb 2026
Advisory Board Members Will Provide Strategic Clinical Insights to Further Advance the TAMP™ Therapy Platform in Clinical Indications of High Unmet Medical Need Advisory Board Members Will Provide S
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
08:30am, Thursday, 05'th Feb 2026
Appointment Strengthens RenovoRx's C-Suite Leadership to Support Commercial Growth of RenovoCath® Appointment Strengthens RenovoRx's C-Suite Leadership to Support Commercial Growth of RenovoCath®
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
08:30am, Wednesday, 04'th Feb 2026
Results Support TAMP's Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-Delivery Results Support TAMP's No
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
08:30am, Wednesday, 28'th Jan 2026
MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies,
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
08:30am, Wednesday, 14'th Jan 2026
CEO Shaun Bagai to Discuss RenovoRx's Commercial and Clinical Program Progress CEO Shaun Bagai to Discuss RenovoRx's Commercial and Clinical Program Progress
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
08:30am, Thursday, 08'th Jan 2026
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx's TAMP Therapy Platform as a Targeted Drug-Delivery Approach
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
08:30am, Thursday, 11'th Dec 2025
MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
